Chemotherapy, which increases the expression of PD-L1 on tumor cells and the number of TILs, has been demonstrated to have few effects in patients characterized by elevated levels of PD-L1 and low levels of causative mutations [104]; thus, the combination between ICIs and chemotherapy could have promising clinical results [105,106]. This evidence concerns the gene CD274 and neoplasm.